Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp in CD123+ or BPDCN-like AML
NCT04342962Phase 2Terminated
- Sponsor
- GIMEMA
- Start
- Feb 2021
- Primary completion
- Jan 2024
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of tagraxofusp in acute myeloid leukemia (AML), sponsored by GIMEMA. Started Feb 2021; status: terminated.
02
Drugs
tagraxofusp
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04342962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04342962.